Skip to main content

2 Result(s)

within Yosuke Hirasawa Remove this filter Medicine & Public Health Remove this filter

and
Your search also matched 5 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you. results, e.g.

C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma

Include preview-only content

  1. Article

    Open Access

    Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan

    Enfortumab vedotin (EV) is a novel antibody–drug conjugate approved for metastatic urothelial carcinoma (UC) refractory to prior treatment with immune checkpoint inhibitors (ICIs). However, the difference in e...

    Yosuke Hirasawa, Takahiro Adachi… in Journal of Cancer Research and Clinical On… (2024)

    Download PDF (688 KB) View Article

  2. Article

    Open Access

    Clinical value of minimum apparent diffusion coefficient for prediction of clinically significant prostate cancer in the transition zone

    This study investigated the association between apparent diffusion coefficients in Prostate Imaging Reporting and Data System 4/5 lesions and clinically significant prostate cancer in the transition zone.

    Ashita Ono, Takeshi Hashimoto… in International Journal of Clinical Oncology (2023)

    Download PDF (822 KB) View Article